Gossamer Bio (Gossamer Bio) Capex-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Gossamer Bio's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Gossamer Bio Capex-to-Revenue Historical Data

The historical data trend for Gossamer Bio's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Capex-to-Revenue Chart

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

Get a 7-Day Free Trial

Gossamer Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Gossamer Bio's Capex-to-Revenue

For the Biotechnology subindustry, Gossamer Bio's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gossamer Bio's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gossamer Bio's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gossamer Bio's Capex-to-Revenue falls into.

Gossamer Bio Capex-to-Revenue Calculation

Gossamer Bio's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Gossamer Bio's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Gossamer Bio (NAS:GOSS) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Gossamer Bio Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio (Gossamer Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

4GB:Germany

Address

3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Executives

Sandra Milligan	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Bryan Giraudo	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Richard Aranda	officer: Chief Medical Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain	director, officer: Executive Chairman	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waage Christian	officer: EVP & General Counsel	RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson	officer: EVP, Regulatory Affairs	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Laura Carter	officer: Chief Scientific Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid	officer: Chief Scientific Officer	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont	officer: Chief Medical Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi	director, officer: President & CEO	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox	director	C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2